Recombinant Insulin (Humulin)

NCERT grounding

NCERT Class XII Biology, Chapter 10 — Biotechnology and its Applications, section 10.2.1 Genetically Engineered Insulin — opens the entire "rDNA in medicine" thread with this case study. Two textbook sentences carry almost every NEET question on the topic, and you should hold them in working memory while reading the rest of this page.

"Insulin consists of two short polypeptide chains: chain A and chain B, that are linked together by disulphide bridges… In mammals, including humans, insulin is synthesised as a pro-hormone… which contains an extra stretch called the C peptide. This C peptide is not present in the mature insulin and is removed during maturation into insulin."

"In 1983, Eli Lilly an American company prepared two DNA sequences corresponding to A and B chains of human insulin and introduced them in plasmids of E. coli to produce insulin chains. Chains A and B were produced separately, extracted and combined by creating disulfide bonds to form human insulin."

NIOS Senior Secondary Biology Lesson 30 reinforces the same narrative within its Genetic Engineering section: insulin from cattle and pig pancreas worked but provoked allergic responses, so an identical-to-human product was needed; recombinant DNA technology let bacteria — organisms that normally do not make insulin at all — synthesise the human chains, after which assembly was performed chemically. Every NEET question in this lane lives inside these two pages.

Structure, pro-insulin and the Eli Lilly route

Insulin is the peptide hormone secreted by the β-cells of the islets of Langerhans in the pancreas. It is the body's principal regulator of blood-glucose uptake, glycogenesis, lipogenesis and protein synthesis. In type-1 diabetes the β-cells are destroyed; in advanced type-2 diabetes endogenous secretion is insufficient. In both cases the therapy is the same — life-long, exogenous insulin administered by injection.

For decades the only source of injectable insulin was the pancreas of slaughtered cattle and pigs. Bovine and porcine insulin differ from the human molecule at a small handful of amino-acid positions, and that is enough: a fraction of patients mount immune responses — local allergic reactions, antibody-driven loss of potency, occasionally anaphylaxis. There was also a hard supply ceiling. The pancreas of one pig yields milligrams of insulin; a single diabetic patient may consume several hundred milligrams per year; the global diabetic population numbers in the hundreds of millions. The animal-source route could not scale.

The mature molecule: two chains, three disulphide bridges

Mature human insulin is a small protein of 51 amino acids arranged as two short polypeptide chains. Chain A is 21 amino acids long; chain B is 30 amino acids long. The two chains are not fused end-to-end. Instead they are held together by two interchain disulphide bridges — covalent S–S bonds linking specific cysteine residues. A third, intrachain disulphide loop within chain A stabilises the A-chain itself. Cleave any of these bridges and the molecule unfolds into inert fragments.

How the body actually makes it: pro-insulin

Inside a healthy β-cell, insulin is not synthesised as two separate chains. It is translated as a single polypeptide called pro-insulin — a pro-hormone in which the B chain, a connecting C-peptide ("connecting peptide") and the A chain are joined head-to-tail in the order B–C–A. While still a single chain, the molecule folds, and the cysteines align so that the eventual A–B disulphide bridges form between residues that are presently very far apart in the linear sequence.

Maturation is then a precise cleavage event. Specific endopeptidases (pro-hormone convertases PC1/PC3 and PC2, with carboxypeptidase E trimming the ends) cut the C-peptide out at two paired-basic sites. What remains are the A chain and the B chain, still tethered by the disulphide bridges that formed earlier. The C-peptide is discarded and is absent from mature insulin. It is secreted alongside insulin in equimolar amounts and is used clinically as a marker of endogenous β-cell activity — but it is not part of the active hormone.

Why this matters for rDNA — the "main challenge"

NCERT singles out one obstacle for production of insulin by rDNA: "getting insulin assembled into a mature form". If you simply clone the entire human pro-insulin coding sequence into E. coli, the bacterium will dutifully translate the B–C–A polypeptide — and stop there. E. coli does not have the eukaryotic pro-hormone convertases that excise the C-peptide; it cannot perform the post-translational cleavage that mammalian β-cells perform without thinking. The pro-insulin sits in the bacterial cytoplasm, often as an insoluble inclusion body, and is not active.

The Eli Lilly route (1983, USA)

In 1983 the American pharmaceutical company Eli Lilly obtained the first regulatory clearance for a recombinant therapeutic in humans, branding the product Humulin (the name advertises both its source — humans — and its host — the bacterial culture). The strategy was elegant precisely because it avoided the post-translational bottleneck.

Animal insulin vs recombinant Humulin

Animal-source insulin was a workable therapy for half a century, but it carried two structural problems: an immunogenicity gap (because the molecule is not identical to human insulin) and an unscalable supply (because the source is a slaughterhouse by-product). Humulin closes both gaps. Because the cloned DNA encodes the exact human amino-acid sequence, the recombinant product is structurally identical to endogenous human insulin and is non-immunogenic in almost all patients. Because the producer is E. coli grown in stainless-steel fermenters, the supply is essentially unlimited.

Reading the rDNA route as three exam triggers

Every NEET question on this topic so far has been built from a small set of fact-triggers. Internalise them as separate atoms; the questions are then trivial pattern-matches.

What Humulin solves — and what it does not

Humulin solves the structural identity and supply problems of animal insulin. It does not alter the route of administration. Insulin is still a protein; taken orally it would be cleaved by pepsin in the stomach and by pancreatic trypsin and chymotrypsin in the small intestine before it could reach the bloodstream. Diabetic patients must therefore inject recombinant insulin subcutaneously (or, increasingly, deliver it through pumps and inhaled formulations), exactly as they did with animal insulin. NEET sometimes embeds this as a textbook side-question — note that NCERT explicitly asks the student to think about it.

Worked examples

Common confusion & NEET traps